Altre lingue BrightPath Biotherapeutics Co., Ltd.

Azioni

4594

JP3274140007

Mercato chiuso - Japan Exchange Altri mercati azionari 08:00:00 14/05/2024			Variaz. 5gg	Var. 1 gen.
58 ^JPY	+1,75%		-1,69%	-33,33%

2022	Brightpath Biotherapeutics annuncia i dati preclinici su BP1209	CI
2018	Brightpath Biotherapeutics Co. Ltd. riporta i risultati dei guadagni consolidati per i sei mesi terminati il 30 settembre 2018; fornisce una previsione dei guadagni consolidati per l'anno che termina il 31 marzo 2019	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

BrightPath Biotherapeutics Co., Ltd. announced that it has received ¥5.1678 million in funding from Macquarie Group Limited	30/11
BrightPath Biotherapeutics Co., Ltd. announced that it expects to receive ¥5.1678 million in funding from Macquarie Group Limited	14/11
BrightPath Biotherapeutics Co., Ltd.(TSE:4594) dropped from S&P Global BMI Index	19/09/22
BrightPath Biotherapeutics Presents Data on Personalized Neoantigen Cancer Vaccine	14/04/22
BrightPath Biotherapeutics Presents Data on Antibody for Cancer Treatment	14/04/22
BrightPath Biotherapeutics : Presents Preclinical Data on a CD73 antagonist antibody at AACR 2022	13/04/22
BrightPath Biotherapeutics : Presents New Data on Personalized Neoantigen Vaccine at AACR 2022	13/04/22
Brightpath Biotherapeutics Announces Preclinical Data on BP1209	13/04/22
BrightPath Biotherapeutics : Presents New Data on Preclinical Data on BP2301(HER2 CAR-T) at AACR 2022	11/04/22
BrightPath Biotherapeutics : Presents New Data on Personalized Neoantigen Vaccine at AACR 2022	11/04/22
BrightPath Biotherapeutics Co., Ltd. announced that it has received ¥1.427175 billion in funding from Macquarie Bank Limited, Investment Arm	01/02/22
BrightPath Biotherapeutics Co., Ltd. announced that it expects to receive ¥1.427175 billion in funding from Macquarie Bank Limited, Investment Arm	14/01/22
BrightPath Biotherapeutics Co., Ltd. announced that it has received ¥0.585974 million in funding from Merrill Lynch Japan Securities Co., Ltd., Investment Arm	23/04/20
BrightPath Biotherapeutics Co., Ltd. announced that it expects to receive ¥0.585974 million in funding from Merrill Lynch Japan Securities Co., Ltd., Investment Arm	07/04/20
Brightpath Biotherapeutics Co., Ltd. Reports Consolidated Earnings Results for the Six Months Ended September 30, 2018; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2019	09/11/18
Brightpath Biotherapeutics Co., Ltd. Reports Consolidated Earnings Results for the First Quarter Ended June 30, 2018; Provides Earnings Guidance for the Year Ending March 31, 2018	10/08/18
BrightPath Biotherapeutics Co., Ltd. Reports Consolidated and Non-Consolidated Earnings Results for the Year Ended March 31, 2018; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2019	11/05/18
BrightPath Biotherapeutics Co., Ltd. Reports Consolidated Earnings Results for the Third Quarter Ended December 31, 2017; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2018	14/02/18
BrightPath Biotherapeutics Co., Ltd. announced that it has received ¥12.1744 million in funding from Credit Suisse Securities Limited, Investment Arm	08/12/17
BrightPath Biotherapeutics Co., Ltd. announced that it expects to receive ¥12.17 million in funding from Credit Suisse Securities Limited, Investment Arm	22/11/17

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue BrightPath Biotherapeutics Co., Ltd.

Azioni

4594

JP3274140007

Altre lingue

Filtri